68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer

Journal of Nuclear Medicine

Wei Zhang¹  Zhaohui Zhu¹  Kun Zheng¹  Lixin Lang¹  Jun Zhao¹  Naixin Liang¹  Xiaoyuan Chen¹  Jingjing Zhang¹  Gang Niu¹  Fang Li¹  Shanqing Li¹ 

关键词: integrin;    ⁶⁸Ga-NOTA-PRGD2;    PET/CT;    lung cancer;    lymph node metastasis;   

DOI  :  10.2967/jnumed.115.160648

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

This study was designed to assess the diagnostic value of 68Ga-NOTA-PRGD2 (NOTA-PRGD2 is NOTA-PEG4-E[c(RGDfK)]2) PET/CT in lung cancer. Methods: Ninety-one patients (48 men and 43 women; age, 22–82 y) with suspected lung lesions on CT were enrolled with informed consent. Immediately after intravenous injection of 117.7 ± 37.7 MBq of 68Ga-NOTA-PRGD2, 15 patients underwent dynamic whole-body PET/CT scans for 1–2 h, and the remaining 76 patients underwent whole-body PET/CT scans at 30 ± 10 min after bolus injection. Each patient also underwent standard 18F-FDG PET/CT for comparison. Results: No side effect was found after 68Ga-NOTA-PRGD2 injection. 68Ga-NOTA-PRGD2 was rapidly cleared from the blood pool and primarily excreted through the urinary system. The standardized uptake values of proven malignancies were significantly higher than those of the benign ones. With an average standardized uptake value of greater than 1.3 being considered malignant, the sensitivity, specificity, and accuracy of 68Ga-NOTA-PRGD2 PET/CT in diagnosing lung cancer were 83.8% (57/68), 91.3% (21/23), and 85.7% (78/91), respectively. The diagnostic value of 68Ga-NOTA-PRGD2 for lung cancer is comparable to that of 18F-FDG PET/CT. However, 68Ga-NOTA-PRGD2 PET/CT is more specific than 18F-FDG PET/CT in assessing lymph node metastasis, with positive and negative predictive values of 90.0% (27/30) and 93.8% (121/129), respectively, whereas those of 18F-FDG PET/CT were 30.2% (29/96) and 90.5% (57/63), respectively. Conclusion: This study indicates the efficacy of 68Ga-NOTA-PRGD2 PET/CT in lung cancer diagnosis. 68Ga-NOTA-PRGD2 PET/CT shows significant advantage over 18F-FDG PET/CT in judging metastatic lymph nodes with higher specificity.

【 授权许可】

Unknown